- Home
- FEMY vs ACCL Comparison
FEMY vs ACCL Comparison
Compare FEMY & ACCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- ACCL
- Stock Information
- Founded
- FEMY 2004
- ACCL 2009
- Country
- FEMY United States
- ACCL Hong Kong
- Employees
- FEMY N/A
- ACCL N/A
- Industry
- FEMY Medical/Dental Instruments
- ACCL Professional Services
- Sector
- FEMY Health Care
- ACCL Consumer Discretionary
- Exchange
- FEMY Nasdaq
- ACCL Nasdaq
- Market Cap
- FEMY 30.2M
- ACCL 32.1M
- IPO Year
- FEMY 2021
- ACCL 2025
- Fundamental
- Price
- FEMY $0.94
- ACCL $4.21
- Analyst Decision
- FEMY Strong Buy
- ACCL
- Analyst Count
- FEMY 3
- ACCL 0
- Target Price
- FEMY $7.33
- ACCL N/A
- AVG Volume (30 Days)
- FEMY 15.7M
- ACCL 313.4K
- Earning Date
- FEMY 11-10-2025
- ACCL 11-24-2025
- Dividend Yield
- FEMY N/A
- ACCL N/A
- EPS Growth
- FEMY N/A
- ACCL N/A
- EPS
- FEMY N/A
- ACCL 0.09
- Revenue
- FEMY $1,887,016.00
- ACCL $4,874,058.00
- Revenue This Year
- FEMY $81.63
- ACCL N/A
- Revenue Next Year
- FEMY $158.53
- ACCL N/A
- P/E Ratio
- FEMY N/A
- ACCL $45.58
- Revenue Growth
- FEMY 98.61
- ACCL 17.95
- 52 Week Low
- FEMY $0.31
- ACCL $2.10
- 52 Week High
- FEMY $1.80
- ACCL $5.00
- Technical
- Relative Strength Index (RSI)
- FEMY 64.01
- ACCL N/A
- Support Level
- FEMY $0.61
- ACCL N/A
- Resistance Level
- FEMY $0.88
- ACCL N/A
- Average True Range (ATR)
- FEMY 0.14
- ACCL 0.00
- MACD
- FEMY 0.03
- ACCL 0.00
- Stochastic Oscillator
- FEMY 68.28
- ACCL 0.00
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.